Literature DB >> 18195690

Inhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin.

David Hernández-Espinosa1, Antonia Miñano, Constantino Martínez, Adriana Ordoñez, Elena Pérez-Ceballos, Felipe de Arriba, Rubén A Mota, Francisca Ferrer, Marcos González, Vicente Vicente, Javier Corral.   

Abstract

Conformational diseases include heterogeneous disorders sharing a similar pathological mechanism, leading to intracellular aggregation of proteins with toxic effects. Serpins are commonly involved in these diseases. These are structurally sensitive molecules that modify their folding under even minor genetic or environmental variations. Indeed, under normal conditions, the rate of misfolding of serpins is high and unfolded serpins must be degraded by the proteasome system. Our aim was to study the effects of bortezomib, a proteasome inhibitor, on conformationally sensitive serpins. The effects of bortezomib were analysed in patients with multiple myeloma, HepG2 cells, and Swiss mice, as well as in vitro. Levels, anti-FXa activity, heparin affinity, and conformational features of antithrombin, a relevant anticoagulant serpin, were analysed. Histological, ultrastructural features and immunohistological distribution of antithrombin and alpha1-antitrypsin (another hepatic serpin) were evaluated. We also studied the intracellular accumulation of conformationally sensitive (fibrinogen) or non-sensitive (prothrombin) hepatic proteins. The inhibition of the proteasome caused intracellular accumulation and aggregation of serpins within the endoplasmic reticulum that was associated with confronting cisternae and Mallory body formation. These effects were accompanied by a heat stress response. Bortezomib also increased the levels of intracellular fibrinogen, but has no significant effect on prothrombin. Finally, bortezomib had only minor effects on the mature circulating antithrombin, with increased amounts of latent antithrombin in plasma. These results suggest that the impairment of proteasomal activities leads to an intracellular accumulation of conformationally sensitive proteins and might facilitate the release of misfolded serpins into circulation where they adopt more stable conformations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18195690     DOI: 10.1038/labinvest.3700717

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  5 in total

1.  The unfolded protein response transducer IRE1α prevents ER stress-induced hepatic steatosis.

Authors:  Kezhong Zhang; Shiyu Wang; Jyoti Malhotra; Justin R Hassler; Sung Hoon Back; Guohui Wang; Lin Chang; Wenbo Xu; Hongzhi Miao; Roberta Leonardi; Y Eugene Chen; Suzanne Jackowski; Randal J Kaufman
Journal:  EMBO J       Date:  2011-03-15       Impact factor: 11.598

2.  Enhancement of ubiquitin conjugation activity reduces intracellular aggregation of V76D mutant γD-crystallin.

Authors:  Zhenzhen Liu; Allen Taylor; Yizhi Liu; Mingxing Wu; Xiaohua Gong; Fu Shang
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-09-25       Impact factor: 4.799

3.  Identification of a novel alpha1-antitrypsin variant.

Authors:  Camille de Seynes; C Ged; H de Verneuil; N Chollet; M Balduyck; C Raherison
Journal:  Respir Med Case Rep       Date:  2016-11-18

4.  UPR pathways combine to prevent hepatic steatosis caused by ER stress-mediated suppression of transcriptional master regulators.

Authors:  D Thomas Rutkowski; Jun Wu; Sung-Hoon Back; Michael U Callaghan; Sean P Ferris; Jahangir Iqbal; Robert Clark; Hongzhi Miao; Justin R Hassler; Jamie Fornek; Michael G Katze; M Mahmood Hussain; Benbo Song; Jayanth Swathirajan; Junying Wang; Grace D-Y Yau; Randal J Kaufman
Journal:  Dev Cell       Date:  2008-12       Impact factor: 12.270

5.  IGF-1 induces the epithelial-mesenchymal transition via Stat5 in hepatocellular carcinoma.

Authors:  Chuanzong Zhao; Qian Wang; Ben Wang; Qi Sun; Zhaobin He; Jianguo Hong; Florian Kuehn; Enyu Liu; Zongli Zhang
Journal:  Oncotarget       Date:  2017-12-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.